graft versus host disease

News

FDA clears Orca's cell therapy Tregzi for GvHD

Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.

News

Mesoblast finally pushes GvHD cell therapy over finish line

At its third attempt, Mesoblast has secured FDA approval for the first-ever mesenchymal stem cell (MSC) therapy, Ryoncil for acute GvHD in children.

News

MaaT Pharma's chief executive and co-founder Hervé Affagard

MaaT microbiota drug shows survival advantage in GvHD

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access pro

News

Mesoblast lifts off as FDA agrees to review GvHD drug again

Regulator has started a priority review of the cell therapy, with a decision due by 2nd August.

News

Equillium triples clinical pipeline with $329m Bioniz takeov...

Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire Bioniz Therap

News

BMS' Orencia gets FDA nod for GvHD thanks to real-world data

Bristol-Myers Squibb's rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem cell transpl

FDA clears Orca's cell therapy Tregzi for GvHD

Mesoblast finally pushes GvHD cell therapy over finish line

MaaT microbiota drug shows survival advantage in GvHD

Mesoblast lifts off as FDA agrees to review GvHD drug again

Equillium triples clinical pipeline with $329m Bioniz takeov...

BMS' Orencia gets FDA nod for GvHD thanks to real-world data

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

graft versus host disease

Editor's Picks